ABT — Abbott Laboratories Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for Abbott Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	3,687	4,495	7,071	6,933	5,723
Depreciation
Amortisation
Non-Cash Items	766	971	695	900	770
Discontinued Operations
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-1,331	-892	-771	-1,519	-2,475
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Cash from Operating Activities	6,136	7,901	10,533	9,581	7,261
Capital Expenditures	-1,638	-2,177	-1,885	-1,777	-2,202
Purchase of Fixed Assets
Other Investing Cash Flow Items	-177	-38	-123	37	-931
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-1,815	-2,215	-2,008	-1,740	-3,133
Financing Cash Flow Items	0	-11	0	—	—
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-4,289	-2,779	-5,494	-7,636	-7,091
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	16	2,978	2,961	83	-2,986